Navigation Links
Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference

PRINCETON, N.J., Jan. 31 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference at 9:20 a.m. ET on Thursday, February 7, 2008. The event will be webcast live and will be available in the Investor Relations section of the Medarex Web site at An archived edition of the presentation will be available following the event.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase III clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its Web site at

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
2. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
3. Medarex to Present at the JPMorgan Small/Mid Cap Conference
4. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
5. 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation
6. Womans Day Presents the 5th Annual Red Dress Awards Honoring Women Who Are Leaders in the Fight Against Heart Disease
7. Moog to Present at Cowen & Co. Aerospace and Defense Conference on February 5, 2008
8. Center for Science Writings presents: Big Fat Lies: The Truth about Diet, Exercise and Obesity
9. Stryker to Present at Investor Conference
10. AMICAS to Present at UBS Global Healthcare Services Conference
11. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... offering factory direct sauna parts and accessories. , Sauna accessories help improve ... the bather’s style and personality. From basic styles for the purist looking for ...
(Date:11/25/2015)... (PRWEB) , ... November 26, 2015 , ... ... Union Commission (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and ... Office in Nairobi (UNON) for the opening of the 5th African Network for ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... For the ... companies’ “ Two Organizations, One Beat ” campaign. The partnership between the two groups ... to aid in MAP International’s cause. , MAP International was founded in 1954 and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview ... the country to celebrate their sobriety and show through pictures what a positive ... after” photos this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, Twitter, and ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug ... a new cutting edge recovery program that has been 50 years in the making. ... individuals with the purpose to free addicts from the symptoms and negative behaviors of ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 --> ... SyMRI to find optimal contrast weighting of MRI for ... has signed a research agreement with SyntheticMR in order to ... SyMRI, it is possible to generate multiple contrast images from ... patient has left, thus making it possible to both fine ...
(Date:11/26/2015)... SAN FRANCISCO , November 26, 2015 ... 1.82 billion by 2022, according to a new report by ... as Chronic Kidney Disease (CKD) which demands kidney transplantation is ... convenient and cost effective substitute for organ transplantation. --> ... 1.82 billion by 2022, according to a new report by ...
(Date:11/26/2015)... ) has ... Future Horizons and Growth Strategies in the ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> ) has announced the ... and Growth Strategies in the French Drugs ...
Breaking Medicine Technology: